Why IVERIC bio Rallied Today

IVERIC bio's Rally
IVERIC Bio (ISEE) announced that the U.S. (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP), also known as Zimura®.

Zimura is a novel investigational complement C5 inhibitor aimed at treating geographic atrophy (GA) secondary to Age-Related . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.